Moderate

Central diabetes insipidus (AVP deficiency) - chronic management

AVP-D · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Deficient vasopressin secretion (now termed AVP-deficiency) causing polyuria and polydipsia, from pituitary/hypothalamic damage. Long-term management centres on desmopressin with vigilance for hyponatraemia and adipsia.

Red flags

  • Hyponatraemia with confusion/seizures (desmopressin excess/water retention)
  • Adipsia with wide sodium swings
  • Rapid-onset severe polyuria with a new pituitary lesion
  • Coexisting untreated adrenal insufficiency masking diabetes insipidus

Assessment

Differential diagnosis

  • Nephrogenic diabetes insipidus (AVP resistance)
  • Primary polydipsia
  • Osmotic diuresis (hyperglycaemia)
  • Drug-induced polyuria
  • Hypercalcaemia/hypokalaemia polyuria

Investigations

  • Paired serum and urine osmolality
  • Water deprivation test or copeptin-based testing (hypertonic saline/arginine stimulation)
  • Serum sodium, glucose, calcium and potassium
  • Pituitary MRI (loss of posterior bright spot, lesion)
  • Anterior pituitary hormone screen

Management

  • Confirm hypotonic polyuria and distinguish central from nephrogenic and primary polydipsia
  • Use copeptin-based testing where available for accurate differentiation
  • Image the pituitary/hypothalamus and screen anterior pituitary function
  • Start desmopressin and titrate to control symptoms while allowing intermittent breakthrough diuresis
  • Advise a regular weekly delayed/omitted dose to avoid chronic water retention
  • Educate on thirst-guided fluid intake and recognising hyponatraemia
  • Identify adipsic patients who cannot self-regulate and set fixed fluid/dose regimens
  • Monitor sodium regularly, especially after dose changes or illness
  • Provide a medical alert and sick-day guidance
  • Treat any underlying lesion and replace other pituitary hormones as needed

Drugs & doses

Desmopressin 10-20 micrograms intranasally, or 100-400 micrograms PO 2-3 times daily, or 60-240 micrograms sublingual
Desmopressin 1-2 micrograms SC/IV for acute/inpatient use
Replacement of coexisting anterior pituitary deficiencies (e.g. hydrocortisone, levothyroxine)

Disposition

Manage with endocrinology and clear sick-day/surgery plans; admit for symptomatic sodium disturbance and give adipsic patients individualised fixed regimens.

Complications & pitfalls

  • Iatrogenic hyponatraemia
  • Severe hypernatraemic dehydration (especially adipsic patients)
  • Hyponatraemic encephalopathy
  • Mismanagement during intercurrent illness/surgery

Exam pearls

  • Allow a regular breakthrough of dilute urine each week to prevent desmopressin-induced hyponatraemia
  • Adipsic AVP-deficiency is dangerous because thirst no longer protects against sodium swings
  • Untreated cortisol deficiency can mask diabetes insipidus, which unmasks after steroid replacement
  • Copeptin testing is replacing the water deprivation test for accuracy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.